AerCap (AER) Competitors

Royalty Pharma (NASDAQ:RPRX) and AerCap (NYSE:AER) are both large-cap finance companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, analyst recommendations, earnings and institutional ownership.

Do insiders and institutionals have more ownership in RPRX or AER?

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 96.4% of AerCap shares are owned by institutional investors. 18.9% of Royalty Pharma shares are owned by company insiders. Comparatively, 0.5% of AerCap shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the media refer more to RPRX or AER?

In the previous week, Royalty Pharma had 1 more articles in the media than AerCap. MarketBeat recorded 13 mentions for Royalty Pharma and 12 mentions for AerCap. AerCap's average media sentiment score of 1.19 beat Royalty Pharma's score of 1.05 indicating that AerCap is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
AerCap	7 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is RPRX or AER more profitable?

Royalty Pharma has a net margin of 50.53% compared to AerCap's net margin of 32.38%. Royalty Pharma's return on equity of 24.65% beat AerCap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	50.53%	24.65%	14.44%
AerCap	32.38%	13.98%	3.28%

Is RPRX or AER a better dividend stock?

Royalty Pharma pays an annual dividend of $0.84 per share and has a dividend yield of 3.3%. AerCap pays an annual dividend of $1.00 per share and has a dividend yield of 1.0%. Royalty Pharma pays out 43.5% of its earnings in the form of a dividend. AerCap pays out 7.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Do analysts rate RPRX or AER?

Royalty Pharma currently has a consensus target price of $41.67, suggesting a potential upside of 62.13%. AerCap has a consensus target price of $110.83, suggesting a potential upside of 16.34%. Given Royalty Pharma's higher probable upside, equities research analysts plainly believe Royalty Pharma is more favorable than AerCap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
AerCap	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Which has more risk & volatility, RPRX or AER?

Royalty Pharma has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, AerCap has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500.

Does the MarketBeat Community favor RPRX or AER?

AerCap received 230 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 74.43% of users gave AerCap an outperform vote while only 67.86% of users gave Royalty Pharma an outperform vote.

Company	Underperform	Outperform
Royalty Pharma	Outperform Votes 323 67.86%	Underperform Votes 153 32.14%
AerCap	Outperform Votes 553 74.43%	Underperform Votes 190 25.57%

Which has higher earnings and valuation, RPRX or AER?

AerCap has higher revenue and earnings than Royalty Pharma. AerCap is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.36B	6.48	$1.13B	$1.93	13.32
AerCap	$7.58B	2.49	$3.14B	$12.62	7.55

Summary

Royalty Pharma and AerCap tied by winning 9 of the 18 factors compared between the two stocks.